Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1538-7836|16|1|39-43

ISSN： 1538-7933

Source： JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol.16, Iss.1, 2018-01, pp. : 39-43

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of plasma‐derived vs. recombinant FVIII concentrates: a comparative study

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : 204-209

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab and intermediate‐purity plasma‐derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor

By  

JOURNAL OF CLINICAL APHERESIS, Vol. 30, Iss. 1, 2015-02 ,pp. : 50-54

John Wiley & Sons Inc

Access to resources Recommend Favorite

Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4)

By  

Transfusion Medicine and Hemotherapy, Vol. 44, Iss. 5, 2017-08 ,pp. : 351-357

Karger

Access to resources Recommend Favorite

Cellular Stress Induced by Plasma-Derived Factor VIII Products

By  

Transfusion Medicine and Hemotherapy, Vol. 41, Iss. 2, 2014-02 ,pp. : 140-144

Karger

Access to resources Recommend Favorite

SIPPET: insights into factor VIII immunogenicity

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 16, Iss. 1, 2018-01 ,pp. : 36-38

John Wiley & Sons Inc

Access to resources Recommend Favorite